Renalytix and Carna Health Partner to Tackle Kidney Disease
Renalytix and Carna Health have formed a partnership aimed at improving the management of chronic kidney disease (CKD) by integrating Renalytix’s FDA-approved kidneyintelX.dkd test with Carna Health’s AI-driven digital health platform. This collaboration seeks to enhance early identification and risk stratification of at-risk patients, thereby facilitating personalized care interventions and reducing the economic burden of CKD on the healthcare system.
The novel care model will integrate FDA-approved kidneyintelX.dkd™ and Carna Health’s digital health platform to identify at-risk patients, halt disease progression, and slash healthcare costs, significantly benefiting US health systems and providers NEW YORK and BOSTON, May 12, 2026…